UnknownNot Applicable

Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M

United States60 participantsStarted 2018-09-24

Plain-language summary

Alpha 2 macroglobulin (A2M) is a plasma protein that acts as a molecular trap for inflammatory factors such as tumor necrosis factor (TNF). After plasma is enriched for A2M, it may be injected for treating chronic inflammation. Plasma enriched for A2M may be considered as a possible injectable agent to counteract inflammation that may occur with a cervicobrachial pain syndrome. This study reports on an experiencing using A2M to treat cervicobrachial syndrome which was predominant for either musculotendinous or neuralgic features.

Who can participate

Age range23 Years – 77 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusionary Criteria: * All patients had daily disabling cervical brachial pain that was continuously present for at least six months. * After examination by one or both of the authors, patients who were diagnosed as having a condition related to musculotendinous pain (MTPS), neuropathic Thoracic Outlet Syndrome (NTOS), or Complex Regional Pain Syndrome (CRPS) qualified for treatment and inclusion in the chart review. Exclusionary Criteria: * N/A * (retrospective analysis of clinical treatment)

What they're measuring

Brief Pain Inventory (BPI)

Timeframe: Baseline

Patient Global Impression of Change Scale (PGIC)

Timeframe: 3 months

Trial details

NCT IDNCT04066933

SponsorNeurological Associates of West Los Angeles

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12

View on ClinicalTrials.gov More Complex Regional Pain Syndromes trials